Profile data is unavailable for this security.
About the company
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
- Revenue in USD (TTM)0.00
- Net income in USD-33.47m
- Incorporated2016
- Employees22.00
- LocationUnicycive Therapeutics Inc4300 El Camino Real, Suite 210LOS ALTOS 94022United StatesUSA
- Phone+1 (650) 384-0642
- Fax+1 (302) 655-5049
- Websitehttps://unicycive.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Polaryx Therapeutics, Inc | -100.00bn | -100.00bn | 132.56m | 2.00 | -- | 25.01 | -- | -- | -- | -- | -- | 0.112 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -703.28 | -- | -- | -- |
| Artiva Biotherapeutics Inc | 0.00 | -79.19m | 134.26m | 106.00 | -- | 1.04 | -- | -- | -3.25 | -3.25 | 0.00 | 5.26 | 0.00 | -- | -- | 0.00 | -42.29 | -44.57 | -45.24 | -51.09 | -- | -- | -- | -596.66 | -- | -- | 0.0006 | -- | -99.25 | -- | -127.62 | -- | 18.74 | -- |
| Oramed Pharmaceuticals, Inc. | 2.00m | 43.85m | 134.53m | 13.00 | 3.36 | 0.679 | 3.06 | 67.27 | 1.01 | 1.01 | 0.0478 | 4.98 | 0.0104 | -- | -- | 153,846.20 | 22.72 | -- | 23.30 | -- | 0.65 | -- | 2,190.40 | -- | -- | -- | 0.00 | -- | -100.00 | -- | -444.98 | -- | -- | -- |
| vTv Therapeutics Inc | 17.00k | -23.47m | 136.54m | 23.00 | -- | 1.94 | -- | 8,031.73 | -3.32 | -3.32 | 0.0024 | 17.91 | 0.0002 | -- | -- | 739.13 | -39.79 | -96.30 | -46.08 | -- | -- | -- | -166,935.30 | -775.06 | -- | -- | 0.0046 | -- | -- | -18.12 | 8.83 | -- | -- | -- |
| Connect Biopharma Holdings Ltd (ADR) | 762.00k | -50.77m | 138.64m | 62.00 | -- | 2.50 | -- | 181.94 | -0.9144 | -0.9144 | 0.0137 | 0.9926 | -- | -- | -- | 12,290.32 | -- | -61.12 | -- | -66.78 | -- | -- | -6,662.99 | -1,963.00 | -- | -- | 0.00 | -- | -- | -- | 74.84 | -- | 37.04 | -- |
| Immunic Inc | 0.00 | -97.17m | 139.60m | 92.00 | -- | -- | -- | -- | -0.6855 | -0.6855 | 0.00 | -0.0554 | 0.00 | -- | -- | 0.00 | -299.36 | -110.19 | -1,602.57 | -137.47 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.32 | -- | 1.98 | -- |
| Sangamo Therapeutics Inc | 32.88m | -108.91m | 139.99m | 183.00 | -- | 20.21 | -- | 4.26 | -0.4428 | -0.4428 | 0.1326 | 0.0194 | 0.3289 | -- | 5.97 | 179,644.80 | -108.96 | -30.73 | -204.29 | -37.33 | -- | -- | -331.28 | -147.59 | -- | -- | 0.00 | -- | -67.20 | -10.81 | 62.01 | -- | -58.10 | -- |
| Milestone Pharmaceuticals Inc | 0.00 | -58.01m | 140.53m | 33.00 | -- | 6.85 | -- | -- | -0.8938 | -0.8938 | 0.00 | 0.2407 | 0.00 | -- | -- | 0.00 | -68.07 | -48.63 | -75.01 | -52.10 | -- | -- | -- | -1,201.96 | -- | -73.28 | 0.7327 | -- | -100.00 | -- | 30.44 | -- | -39.67 | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -67.51m | 144.11m | 28.00 | -- | 1.12 | -- | -- | -5.51 | -5.51 | 0.00 | 7.35 | 0.00 | -- | -- | 0.00 | -49.34 | -69.78 | -55.11 | -97.84 | -- | -- | -- | -5,894.85 | -- | -- | 0.00 | -- | -- | -- | 9.85 | -- | -- | -- |
| Unicycive Therapeutics Inc | 0.00 | -33.47m | 145.71m | 22.00 | -- | 3.77 | -- | -- | -2.85 | -2.85 | 0.00 | 1.80 | 0.00 | -- | -- | 0.00 | -74.93 | -188.44 | -101.88 | -723.53 | -- | -- | -- | -6,003.20 | -- | -- | 0.00 | -- | -100.00 | -- | -20.42 | -- | -- | -- |
| AVITA Medical Inc | 71.61m | -48.59m | 147.34m | 226.00 | -- | -- | -- | 2.06 | -1.75 | -1.75 | 2.57 | -0.5446 | 1.05 | 1.69 | 6.86 | 316,854.00 | -71.40 | -- | -182.42 | -- | 83.27 | -- | -67.85 | -- | 0.4557 | -8.22 | 1.63 | -- | 11.45 | -- | 21.44 | -- | -- | -- |
| ProQR Therapeutics NV | 18.67m | -49.44m | 158.02m | 166.00 | -- | 2.44 | -- | 8.47 | -0.4754 | -0.4754 | 0.1797 | 0.6153 | 0.139 | -- | 9.70 | 112,450.70 | -36.82 | -29.87 | -53.74 | -35.27 | -- | -- | -264.83 | -501.81 | -- | -- | 0.2242 | -- | 105.20 | 58.84 | 1.27 | -- | 19.58 | -- |
| Fate Therapeutics Inc | 6.65m | -136.32m | 159.28m | 161.00 | -- | 0.7628 | -- | 23.97 | -1.15 | -1.15 | 0.056 | 1.80 | 0.0175 | -- | 2.58 | 41,279.50 | -35.89 | -32.10 | -39.80 | -36.05 | -- | -- | -2,051.08 | -414.22 | -- | -- | 0.00 | -- | -51.24 | -26.71 | 26.82 | -- | 3.83 | -- |
Data as of Mar 03 2026. Currency figures normalised to Unicycive Therapeutics Inc's reporting currency: US Dollar USD
26.95%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Millennium Management LLCas of 16 Jan 2026 | 1.17m | 5.46% |
| Octagon Capital Advisors LPas of 31 Dec 2025 | 1.00m | 4.65% |
| Nantahala Capital Management LLCas of 31 Dec 2025 | 939.20k | 4.37% |
| Great Point Partners LLCas of 31 Dec 2025 | 796.56k | 3.71% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 679.65k | 3.16% |
| Logos Global Management LPas of 31 Dec 2025 | 473.56k | 2.20% |
| Citadel Advisors LLCas of 31 Dec 2025 | 258.30k | 1.20% |
| Cantor Fitzgerald & Co.as of 31 Dec 2025 | 200.00k | 0.93% |
| Geode Capital Management LLCas of 31 Dec 2025 | 171.29k | 0.80% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 101.07k | 0.47% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
